Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2022-11-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
茂名恒颐投资有限公司股东拟转让股权所涉及的茂名恒颐投资有限公司的股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is a detailed asset valuation report for Maoming Hengyi Investment Co., Ltd., prepared by Guizhou Qianyuan Real Estate Asset Appraisal Co., Ltd. It includes extensive financial data, asset and liability details, valuation methods, legal and regulatory references, and audit confirmations. The report is dated November 7, 2022, with an evaluation base date of August 31, 2022. The content is consistent with an asset appraisal report used for shareholder equity valuation in the context of a proposed equity transfer. This type of document is a formal asset evaluation report, which fits the category of an Audit Report / Information (AR) as it is a standalone audit-related valuation report, not a full annual or interim financial report, nor an announcement or presentation. The document length and detail confirm it is the report itself, not just an announcement or certification. Q3 2022
2022-11-28 Chinese
第九届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution regarding the approval of a subsidiary equity transfer. It includes details about the meeting date, attendance, voting results, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial analysis but rather reports a corporate governance decision and transaction approval. It also references a separate announcement for detailed information on the equity transfer. Given the content and nature, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length is short and it is not a full report or financial statement, so it is not an Annual Report, Interim Report, or Capital Update. It is not a Management or Board change announcement either, as it focuses on a transaction approval by the supervisory board. Therefore, the classification is RNS with high confidence.
2022-11-28 Chinese
关于部分董事、监事、高级管理人员减持股份的预披露公告
Director's Dealing Classification · 100% confidence The document is a public announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the pre-disclosure of share reduction plans by certain directors, supervisors, and senior management personnel. It details the number of shares held, the planned reduction amounts, reasons for reduction, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report attached or referenced as being published. The content focuses on insider share transactions by company executives. Therefore, this document fits the category of Director's Dealing (DIRS). The document length is 2338 characters, which is consistent with a detailed announcement rather than a full report.
2022-11-28 Chinese
联合资信评估股份有限公司关于终止广州市香雪制药股份有限公司及“17制药02”信用评级的公告
Delisting Announcement Classification · 95% confidence The document is a public announcement from a credit rating agency about the termination of the credit rating for a specific bond and the company. It references the bond's maturity and delisting (摘牌) after full repayment. The document is short (620 characters) and serves as an official notice rather than a detailed financial report or audit. It does not contain financial statements or detailed analysis but is an announcement related to credit rating termination and bond delisting. This fits best under 'Delisting Announcement' (DLST) as it announces the bond's delisting and termination of rating.
2022-11-24 Chinese
“17制药02”债券兑付兑息暨摘牌公告
Delisting Announcement Classification · 100% confidence The document is an announcement regarding the payment of principal and interest and the delisting (摘牌) of a corporate bond issued by 广州市香雪制药股份有限公司. It details the bond's basic information, payment schedule, tax information, and the delisting date of the bond from the exchange. The document is not a financial report, audit, or earnings release but a formal notice about bond redemption and delisting. The key phrase '债券摘牌公告' (bond delisting announcement) and the detailed description of the bond's delisting date confirm this classification. The document length is 2594 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is Delisting Announcement (DLST).
2022-11-21 Chinese
2017年面向合格投资者公开发行公司债券（第二期）临时受托管理报告
Audit Report / Information Classification · 95% confidence The document is titled as a "临时受托管理事务报告" which translates to "Interim Trustee Management Report" related to a specific bond issuance by 广州市香雪制药股份有限公司. It contains detailed financial data, bond issuance details, liquidity and risk analysis, and updates on litigation and asset disposals. The document references the 2022 third quarter report and half-year report but is itself a standalone report focusing on the bond trustee's management and monitoring activities. It is not an announcement of a report publication, nor a certification or a brief summary. It contains substantive financial and operational information relevant to the bond issuance and its risks. This fits the category of an Audit Report / Information (AR) as it is a standalone report related to bond trustee management and risk monitoring, not a full annual or interim report, nor a regulatory filing or announcement. The document length (4454 characters) is sufficient for a detailed report but not a full annual or quarterly report. Therefore, the best classification is AR with high confidence. 9M 2022
2022-11-03 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.